RenovoRx/$RNXT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About RenovoRx
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
- Ticker
- $RNXT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Mountain View, United States
- Website
- renovorx.com
RenovoRx Metrics
BasicAdvanced
$53M
-
-$0.31
-
-
Price and volume
Market cap
$53M
52-week high
$2.59
52-week low
$0.70
Average daily volume
451K
Financial strength
Current ratio
5.65
Quick ratio
5.267
Long term debt to equity
0.024
Total debt to equity
0.024
Profitability
EBITDA (TTM)
-13.064
Gross margin (TTM)
84.04%
Net profit margin (TTM)
-469.02%
Operating margin (TTM)
-471.04%
Management effectiveness
Return on assets (TTM)
-69.13%
Return on equity (TTM)
-149.98%
Valuation
Price to revenue (TTM)
18.097
Price to book
6.13
Price to tangible book (TTM)
6.13
Price to free cash flow (TTM)
-4.109
Free cash flow yield (TTM)
-24.33%
Free cash flow per share (TTM)
-0.287
Growth
Revenue change (TTM)
199.14%
Earnings per share change (TTM)
-11.68%
3-year earnings per share growth (CAGR)
-30.85%
What the Analysts think about RenovoRx
Analyst ratings (Buy, Hold, Sell) for RenovoRx stock.
Analyst projections of the future price of RenovoRx stock.
RenovoRx Financial Performance
Revenues and expenses
RenovoRx Earnings Performance
Company profitability
Upcoming events
No upcoming events
RenovoRx News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.